Craig-Hallum lowered the firm’s price target on CareDx (CDNA) to $26 from $40 and keeps a Buy rating on the shares. The firm notes CareDx closed down 38.5% on Thursday in the wake of an unfavorable proposed Local Coverage Determination for transplant testing. Craig-Hallum thinks the shares are substantially undervalued at the current price, even if the rule is finalized.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx upgraded to Buy from Hold at Nephron Research
- CareDx’s HeartCare Study: A Game Changer in Transplant Monitoring?
- CareDx’s ALAMO Study: A Game Changer in Lung Transplant Surveillance?
- CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance
- CareDx’s HeartCare Study: A Game-Changer in Transplant Surveillance?